Boston Scientific (NYSE:BSX) Hits New 1-Year Low – Time to Sell?

Shares of Boston Scientific Corporation (NYSE:BSX) reached a new 52-week low on Friday. The company traded as low as $41.94 and last traded at $42.2780, with a volume of 1531121 shares trading hands. The stock had previously closed at $43.23.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BSX shares. Raymond James Financial reissued an “outperform” rating and set a $57.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. BTIG Research cut their target price on Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research note on Wednesday, September 9th. Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a report on Wednesday, July 29th. Needham & Company LLC cut their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, July 8th. Finally, Royal Bank Of Canada lowered their price objective on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, July 30th. Twenty-three analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $70.19.

Boston Scientific Stock Performance

The firm’s 50 day moving average is $46.99 and its 200-day moving average is $51.70. The stock has a market capitalization of $62.20 billion, a price-to-earnings ratio of 17.37, a PEG ratio of 1.05 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the business earned $0.75 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts forecast that Boston Scientific Corporation will post 3.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael Mahoney acquired 186,240 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David Habiger bought 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BSX. QRG Capital Management Inc. increased its stake in Boston Scientific by 129.4% during the 2nd quarter. QRG Capital Management Inc. now owns 375,620 shares of the medical equipment provider’s stock worth $16,031,000 after buying an additional 211,855 shares in the last quarter. Andra AP fonden boosted its stake in shares of Boston Scientific by 13.9% in the second quarter. Andra AP fonden now owns 193,622 shares of the medical equipment provider’s stock worth $8,264,000 after acquiring an additional 23,694 shares during the last quarter. SkyView Investment Advisors LLC purchased a new stake in shares of Boston Scientific during the second quarter worth approximately $107,000. Bullseye Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter valued at $41,000. Finally, Rench Wealth Management Inc. lifted its holdings in Boston Scientific by 27.5% in the 2nd quarter. Rench Wealth Management Inc. now owns 27,952 shares of the medical equipment provider’s stock valued at $1,193,000 after purchasing an additional 6,033 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.